Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial
Author(s):
Rousel, J. (0000-0003-0986-3753); Saghari, M.; Pagan, L.; Nadaban, A. (0000-0002-4981-6268); Gambrah, T.; Theelen, B.; Kam, M.L. de; Haakman, J.; Wall, H.E.C. van der; Feiss, G.L.; Niemeyer-van der Kolk, T.; Burggraaf, J.; Bouwstra, J.A. (0000-0002-7123-6868); Rissmann, R.; Doorn, M.B.A. van
Published
2023
Publication type
Article / Letter to editor
Date issued
2023-09-01
Language
English
Is part of
International Journal of Molecular Sciences (2023), No. 18, 14315
